If you are a Healthcare Professional and you would like to log in to access this content, please click "Login".
You are now leaving the Lilly Medical Web site
Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Cyramza ® (ramucirumab)
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information:
Cyramza Summary of Product Characteristics (SmPC)
Cyramza® (ramucirumab): Use with COVID-19 Vaccines
The use of vaccines against SARS-CoV-2 in patients treated with ramucirumab has not been studied.
of COVID-19 Vaccines to Patients Receiving Ramucirumab
use of vaccines against SARS-CoV-2 in patients treated with
ramucirumab has not been studied.
acute respiratory syndrome coronavirus 2 is an emerging virus that
has caused the recent COVID-19 pandemic. There are several vaccines
against SARS-CoV-2 currently available, and others are under
Vaccination With Ramucirumab
use of a SARS-CoV-2 vaccine in patients treated with Cyramza
(ramucirumab) has not been studied by Lilly.
regarding the use of any vaccination, including SARS-CoV-2 vaccines,
in patients treated with Cyramza should be made at the discretion of
the prescribing physician using their best clinical judgment, and
must be made by the clinician after careful consideration of risk
factors of the patient as well as the risks and benefits of
vaccination. Consultation with an infectious disease expert may be
helpful in high-risk or emergency situations such as the current
Disease Resources for COVID-19 Vaccines
the most up-to-date information regarding each vaccine in
development, please check the World Health Organization and Centers
for Disease Control information at
Jackson LA, Anderson EJ, Rouphael NG, et al; mRNA-1273 Study Group.
An mRNA vaccine against SARS-CoV-2 — preliminary report. N
Engl J Med. 2020;383(20):1920-1931.
= coronavirus disease 2019
= Eli Lilly and Company
= severe acute respiratory syndrome coronavirus 2
Date of Last Review:January 05, 2021
Are you satisfied with this content?
Call or Email us
If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at firstname.lastname@example.org